SCHEDULE 13G/A: Venrock Funds Maintain Significant Passive Stake in Century Therapeutics, Inc.
Beneficial Ownership Amendment
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a continued beneficial ownership of 4.7% of Century Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 3,957,186 shares of Century Therapeutics, Inc. Common Stock.
- This aggregate ownership represents 4.7% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 85,029,042 shares of Common Stock outstanding as of November 1, 2024, as reported by Century Therapeutics, Inc. in its Form 10-Q filed on November 5, 2024.
- The shares are held across three entities: VHCP III (864,143 shares), VHCP Co-Investment III (86,459 shares), and VHCP EG (3,006,584 shares).
- The Reporting Persons share both voting and dispositive power over all 3,957,186 beneficially owned shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is neutral in tone, as expected for a Schedule 13G/A. The continued significant stake by a reputable healthcare investor group could be seen as a mild positive signal of confidence, hence slightly above neutral.
Positives
- Continued significant passive investment by Venrock Healthcare Capital Partners, a reputable healthcare-focused investor group, indicating ongoing confidence in Century Therapeutics, Inc.
Risks
- The Reporting Persons are passive investors and do not intend to influence the control of Century Therapeutics, Inc., meaning their stake does not imply active strategic direction or intervention.
Future Outlook
NA
Industry Context
This filing reflects a passive investment by a healthcare-focused capital partner in a biotechnology company, which is common practice for venture capital and private equity firms in the life sciences sector. The 4.7% stake indicates a significant, but non-controlling, position in Century Therapeutics, Inc., a company likely involved in therapeutic development.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive institutional investor's stake, which may influence market perception of the stock.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which Century Therapeutics, Inc. reported 85,029,042 shares of Common Stock outstanding in its Form 10-Q. |
| 2024-11-05 | Date Century Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date of execution and filing of the Joint Filing Agreement and the Schedule 13G/A. |
Keywords
Century Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, beneficial ownership, institutional investment, common stock, biotechnology, pharmaceuticals, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.